Liang X - Search Results

1

Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one" Scaffold for the Treatment of B Cell Lymphoma.

Liang X, Yu H, Liang R, Feng Z, Saidahmatov A, Sun C, Ren H, Wei X, Zhao J, Yang C, Liu H. Liang X, et al. Among authors: liang r. J Med Chem. 2024 Feb 22;67(4):2884-2906. doi: 10.1021/acs.jmedchem.3c02031. Epub 2024 Feb 13. J Med Chem. 2024. PMID: 38349664

2

Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.

Zang J, Liang X, Huang Y, Jia Y, Li X, Xu W, Chou CJ, Zhang Y. Zang J, et al. Among authors: liang x. J Med Chem. 2018 Jun 28;61(12):5304-5322. doi: 10.1021/acs.jmedchem.8b00384. Epub 2018 Jun 7. J Med Chem. 2018. PMID: 29787262

3

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.

Liang X, Zang J, Li X, Tang S, Huang M, Geng M, Chou CJ, Li C, Cao Y, Xu W, Liu H, Zhang Y. Liang X, et al. J Med Chem. 2019 Apr 25;62(8):3898-3923. doi: 10.1021/acs.jmedchem.8b01597. Epub 2019 Apr 3. J Med Chem. 2019. PMID: 30901208

4

Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors.

Liang X, Liu H, Zhang Y. Liang X, et al. Future Med Chem. 2019 Aug;11(15):1849-1852. doi: 10.4155/fmc-2019-0168. Future Med Chem. 2019. PMID: 31517536 No abstract available.

5

Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.

Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H. Liang X, et al. J Med Chem. 2022 Jan 27;65(2):1243-1264. doi: 10.1021/acs.jmedchem.0c02111. Epub 2021 Feb 15. J Med Chem. 2022. PMID: 33586434

6

MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies.

Liang X, Cao Y, Li C, Yu H, Yang C, Liu H. Liang X, et al. Med Res Rev. 2021 Jul;41(4):2388-2422. doi: 10.1002/med.21799. Epub 2021 Mar 25. Med Res Rev. 2021. PMID: 33763890 Review.

7

Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.

Liang X, Sun C, Li C, Yu H, Wei X, Liu X, Bao W, Shi Y, Sun X, Khamrakulov M, Yang C, Liu H. Liang X, et al. J Med Chem. 2021 Jul 8;64(13):9217-9237. doi: 10.1021/acs.jmedchem.1c00466. Epub 2021 Jun 28. J Med Chem. 2021. PMID: 34181850

8

Discovery of Novel Imidazo[4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis.

Liang X, Xie Y, Liu X, Xu H, Ren H, Tang S, Liu Q, Huang M, Shao X, Li C, Zhou Y, Geng M, Xie Z, Liu H. Liang X, et al. J Med Chem. 2022 Sep 22;65(18):11949-11969. doi: 10.1021/acs.jmedchem.2c00390. Epub 2022 Sep 2. J Med Chem. 2022. PMID: 36053746

9

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.

Liu Q, Liu X, Li Y, Zhou Y, Zhao L, Liang X, Liu H. Liu Q, et al. Among authors: liang x. Chemistry. 2023 Sep 26;29(54):e202301553. doi: 10.1002/chem.202301553. Epub 2023 Aug 14. Chemistry. 2023. PMID: 37370192

10

Construction of Diversified Penta-Spiro-Heterocyclic and Fused-Heterocyclic Frameworks with Potent Antitumor Activity.

Liu Q, Liu X, Li Y, Zhou Y, Zhao L, Liang X, Liu H. Liu Q, et al. Among authors: liang x. Chemistry. 2023 Sep 26;29(54):e202302677. doi: 10.1002/chem.202302677. Epub 2023 Sep 21. Chemistry. 2023. PMID: 37732554

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,913 results

Search Page

Filters